fbpx

Blog

Problems with medicines behind 250,000 hospital admissions annually

31 January 2019

 

A new report has revealed 250,000 Australians are hospitalised each year, with another 400,000 presenting to emergency departments, as a result of medication errors, inappropriate use, misadventure and interactions – at least half of which could have been prevented.

 

The Medicine Safety: Take Care Report, developed for the Pharmaceutical Society of Australia by the Quality Use of Medicines and Pharmacy Research Centre at the University of South Australia, calculates the annual cost of medication-related problems in Australia at nearly $1.4 billion – equivalent to 15 per cent of total PBS expenditure.

 

Speaking at the report’s launch in Melbourne today, PSA National President Dr Chris Freeman said the report revealed the sobering extent of the issue and demonstrated the need for medicine harm to become a national health priority.

 

“Each year, approximately 250,000 Australians are admitted to hospital as a result of medicine-related problems. This is almost four times the annual number of people who are hospitalised as a result of motor vehicle accidents,” he said.

 

“And there is an additional 400,000 presentations annually to emergency departments due to medicine-related problems.

 

“At least 50 per cent of medicine-related problems are preventable, but only if we remove the siloed approach to medicines management.

 

“If medicine harm was a chronic disease it would already be a national health priority. This report highlights that governments, pharmacists and other health professionals need to work together to reduce the alarming incidence of medication errors, misadventure, misuse and interactions,” he said.

 

Report author, Professor Libby Roughead from the Quality Use of Medicines and Pharmacy Research Centre said, “As the use of pharmaceuticals increases so too do rates of medication error, management problems and interactions with other medicines.”

 

The report highlighted that in 2016-17 two thirds of patients visiting GPs took at least one continual medication, with 11 per cent experiencing adverse medication events in the previous six months. “This equates to almost 1.2 million Australian experiencing an adverse medication event in the past six months,” she said.

 

“Four-in-ten older Australians have been prescribed at least one potentially inappropriate medicine, confirming the need for greater checks and balances in the way medicines are prescribed, dispensed and monitored,” she said.

 

PSA argues that increasing the role of pharmacists in medicines management and wherever medicines are used – in residential aged care homes, hospital discharge and in the community – has the potential to significantly reduce the number of adverse events and medication-related hospital admissions.

 

Dr Freeman added, “There is a clear need for pharmacists to lead medication reconciliation and review activities as they are experts in medicines. They are uniquely placed within the healthcare system and the frequency with which they interact with patients means they are equipped to identify a medicine-related issue and resolve it immediately.”

 

“Regular and thorough reviews of medicines are one of the ways to reduce this significant health risk and cost to the community. On average, four medication-related problems are detected for each person who has a home medicines review,” he said.

 

“The report also shows the need for pharmacists to be embedded within residential aged care facilities to tackle the prevalence of medication-related problems that occur in this setting. This could include medication review, clinical governance and educating staff in the quality of use of medicines.”

 

The report findings focus on four areas where medication-related problems are rife:

 

Inappropriate medicine use in residential aged care

  • 98 per cent of people living in aged care facilities have at least one medication-related problem identified at review, and up to 80 per cent are prescribed potentially inappropriate medicine.
  • 17 per cent of unplanned hospital admissions by people living in aged-care facilities are caused by an inappropriate medicine.

 

Hospital discharge is a missed opportunity

  • More than 90 per cent of people have at least one medication-related problem post-discharge from hospital.
  • At least one medication error was identified in 60 per cent of hospital discharge summaries where a pharmacist was not involved in its preparation.
  • Only one-in-five changes made to the medication regimen during hospital admission were explained in the discharge summary.

 

Impaired kidney function is increasingly common in older people

  • One-in-four older people treated with medicines that rely on the kidneys to clear the body are prescribed doses considered excessive.
  • Among people with poor kidney function, at the time of their admission to hospital 16 per cent were receiving a medicine that should not have been prescribed and 21 per cent had been prescribed an inappropriate dose.

 

Multiple medicine use spells danger

  • The use of multiple medicines was responsible for 70 per cent of cases where people are admitted to hospital for adverse drug reactions.

 

Read the full report here.

 

For more information or to arrange an interview with Dr Chris Freeman or Professor Libby Roughead, please contact Jay Pleass on 0412 623 578 or (02) 8904 7300.

Alyssa Murray wins Pharmacy Student of the Year Wildcard

Sunday January 27, 2019

 

Alyssa Murray from Queensland has won the National Australian Pharmacy Students’ Association (NAPSA) Wildcard for the 2019 PSA Pharmacy Student of the Year (PSOTY) Award.

 

PSA National President Dr Chris Freeman announced the award at the NAPSA Congress Gala Ball in Adelaide tonight.

 

Dr Freeman congratulated Ms Murray on her exceptional achievement.

 

“Ms Murray and all of the finalists demonstrated exceptional counselling skills and impressive pharmacy knowledge,” Dr Freeman said.

 

“It was great to see so much talent on display at the competition today.

 

“Seeing these rising stars in action fills me with confidence about the future of the profession.”

 

Ms Murray is completing a Bachelor of Pharmacy at the University of Queensland and is a member of the Queensland Pharmacy Students Association (QPSA).

 

The judges were impressed by the strong field of finalists:

 

  • Noor Shoaib, La Trobe University (VIC)
  • Vivien Banks, University of Queensland (QLD)
  • Jacqui Leggett, Queensland University of Technology (QLD)
  • Stephanie Samios, University of Queensland (QLD)
  • Sean Richardson, University of South Australia (SA)

 

The award is proudly sponsored by Mylan.

 

Ms Murray will now travel to PSA’s national conference PSA19 from 26 to 28 July 2019 in Sydney to compete in the prestigious national final.

 

“PSA thanks Mylan for their fantastic support of this award,” Dr Freeman said.

 

Media contact:
Jarryd Luke
Senior Communications Officer
0487 922 176
media@psa.org.au

Pharmacists recognised in Australia Day Honours

Saturday January 26, 2019

 

Respected pharmacists and PSA members Grant Kardachi FPS, Dr Geraldine Moses FPS, Emil Dan FPS, Dr Carol Armour FPS and Dr Ross Holland FPS have been congratulated by the Pharmaceutical Society of Australia (PSA) for being awarded the status of Member of the Order of Australia (AM).

 

PSA also applauds PSA members Geoffrey Pritchard FPS, Leonard Levy MPS and Robert Kalaf MPS for receiving the Medal of the Order of Australia (OAM).

 

Pharmacists Jim Siderov, Paul Sinclair and Bakhos Georges were also honoured with the Member of the Order of Australia during the Australia Day celebrations last night.

 

PSA National President Dr Chris Freeman congratulated all of the pharmacists who were recognised.

 

“I applaud all of the exceptional pharmacists for their tireless dedication to their profession, to their community’s health and to their peak national body, PSA,” Dr Freeman said.

 

“The pharmacy profession has been well represented in this year’s awards. It’s inspiring to see so many pharmacists honoured for their pioneering work to improve Australia’s health.

 

“These respected leaders and role models have set an inspiring example for our profession.”

 

Mr Kardachi from Unley Park in South Australia is a past National President and current National Board Director of PSA. Mr Kardachi has owned several community pharmacies while supporting research projects in medication management. He has served the state of South Australia through various foundations, boards and committees.

 

From Corinda in Queensland, Dr Moses is a hospital-based drug information consultant and clinical pharmacist. She provides the Australian Dental Association’s national drug information advisory service Pharma-Advice. Dr Moses is an adjunct associate professor at the University of Queensland and co-founder of medicines education service Pharmeducation. She has served as a member of the PSA Queensland Branch Committee and received PSA’s prestigious Bowl of Hygeia Award in 1993.

 

Mr Dan from Marourbra in NSW received a PSA Lifetime Award of Excellence in 2009 and has since become a PSA Life Fellow. He was an early pioneer of asthma research in Australia, founding the anti-allergy and asthma treatment initiative Allersearch. His groundbreakng work in this area also includes research for smoking cessation services in pharmacy at the Woolcock Institute of Respiratory Medicine, and lecturing for PSA and the Asthma Foundation.

 

Dr Armour is a Professor of Pharmacy and Associate Dean of Career Development, Sydney Medical School at the University of Sydney. She was recognised for significant service to medical education and asthma management.

 

Dr Holland was recognised for significant service to pharmacy practice, medical education and professional organisations. Hailing from NSW, he is a PSA Life Fellow and has served as the Dean of Academic Studies at the Australian College of Pharmacy Practice. He is a Past Faculty Member of the World Health Organisation Regional Teacher Training Centre, South Korean Clinical Pharmacy Association.

 

Recognised for his service to the pharmacy profession, Mr Pritchard from Milsons Point in NSW is a PSA Life Fellow and served as a Liaison Officer for the PSA NSW Branch. His contributions include Director of Pharmacy Services at the Sydney Olympic Games and a number of roles at the Pharmacy Council of New South Wales.

 

Mr Levy from North Caulfield in Victoria has made longstanding contributions to the Victorian Branch of PSA, including as a Councillor and Chair of various committees. He has contributed many years of service to the Pharmacy Board of Victoria.

 

Mr Kalaf has worked as a pharmacist at Cooranbong Pharmacy and Compounding in NSW for more than 25 years. His community service roles include President of the Cooranbong Chamber of Commerce, Member of the Sewerage Development Committee and Member of the Tidy Towns Committee.

 

Media contact:
Jarryd Luke
Senior Communications Officer
0487 922 176

Pharmacists support pill testing

January 23, 2019

 

In the wake of recent deaths from illicit drug use at festivals, pill testing and drug checking services should be trialled in Australia, according to a new position statement by the Pharmaceutical Society of Australia (PSA).

 

PSA National President Dr Chris Freeman said PSA believed further pill testing trials should be conducted at music festivals and other environments where illicit drug use occurs.

 

PSA’s position supports the recent call by the Royal Australasian College of Physicians as well as other medical groups to implement further pill testing trials at music festivals.

 

Pill testing is a harm minimisation service that analyses the content of illicit drugs to warn people about unknown and potentially lethal contaminants. In 2011, illicit drug use caused 2.3% of the total burden of disease and injury in Australia.

 

Dr Freeman said PSA considers pill testing to be consistent with the principles of harm reduction and supports further trials to inform the role of pill testing in Australia.

 

“Pill testing informs people of the risks of illicit drugs without giving the impression that the drugs are safe – they are still illegal and potentially harmful,” he said.

 

“Pill testing was successfully trialled at the Groovin’ The Moo festival in Canberra last year, and PSA supports further trials in each jurisdiction in Australia.”

 

Pharmacists have a long and established role in harm minimisation, from Opioid Replacement Therapy and needle and syringe programs to providing naloxone.

 

However, Australia is lagging behind other countries where pharmacists play a more prominent role in minimising harm from illicit drugs.

 

“Outside of emergency settings, Australia has no ongoing sanctioned pill testing services, even though evidence shows young people are supportive of these services and would use them,” Dr Freeman said.

 

“Several European countries already provide these services, including the Netherlands, Austria, Portugal and France.

 

“The evidence from Europe is clear: pill testing saves lives. It’s time to invest in national trials and research so we can make informed decisions about pill testing.

 

“Law enforcement by itself does not stop people from dying but pill testing, as a supplement strategy, can.”

 

Media contact:
Jarryd Luke
Senior Communications Officer
0487 922 176

Pharmacy banner and buying groups urged to remove homeopathy from their shelves

Community pharmacy banner and buying groups should draw a line in the sand and cease all activities that encourage the stocking, promotion, recommendation or marketing of homeopathy, the Pharmaceutical Society of Australia (PSA) said today.

 

PSA National President Dr Chris Freeman published an open letter and wrote to major banner and buying groups, stating that many people were not aware that there was no reliable evidence for the use of homeopathic products.

 

“Public health is put at risk if people choose homeopathy over treatments that evidence shows are safe and effective,” he said.

 

PSA provided advice to pharmacists in its Choosing Wisely recommendations last month. One of the six recommendations is: “Do not promote or provide homeopathic products as there is no reliable evidence of efficacy. Where patients choose to access homeopathic treatments, health professionals should discuss the lack of benefit with patients.”

 

“Where there are homeopathic products available from community pharmacies, patients may see this as a de-facto endorsement,” Dr Freeman said.

 

The supply of homeopathic products is in contravention of the PSA Code of Ethics for Pharmacists. The Code of Ethics, recognised by the Pharmacy Board of Australia, states that pharmacists should only “supply or promote any medicine, complementary medicine, herbal remedy or other healthcare product where there is credible evidence of efficacy and the benefit of use outweighs the risk.”

 

“The PSA Code of Ethics makes it clear that homeopathic products should not be stocked or sold in community pharmacies. Banner and buying groups should do everything in their power to remove these products from their shelves,” Dr Freeman said.

 

“I congratulate the community pharmacists who have made the decision to remove these products from their shelves, or are planning to do so. We need to lead by example so patients continue to see community pharmacy as a health destination that provides the best possible evidence-based care.

 

“I look forward to community pharmacy groups committing to ensure patients receive robust health advice and are not misled into believing homeopathic products have any evidence of benefit.”

 

Media contact:
Jarryd Luke
Senior Communications Officer
0487 922 176

PSA supports Uluru Statement from the Heart

January 10, 2019

 

The Pharmaceutical Society of Australia (PSA) has endorsed the historic Uluru Statement from the Heart, which calls for a First Nations Voice to be enshrined in the Constitution and for a Makarrata Commission as a process for agreement making and truth telling.

 

PSA National President Dr Chris Freeman said PSA was proud to add its voice to the call for recognition of the First Peoples of Australia in the Constitution.

 

“PSA is committed to ongoing work to support the health and wellbeing of Aboriginal and Torres Strait Islander people. We support the Uluru Statement from the Heart’s call for constitutional reforms to empower people to have their views heard in relation to making laws and policies that affect their lives.

 

“We are proud to add our voice to this movement for a better future.”

 

Generational disadvantage continues to have a detrimental impact on the physical and mental health of Aboriginal and Torres Strait Islander people.

 

“As the peak national body for pharmacists, PSA has long advocated for closing the gap by supporting pharmacists to play an active role in improving medication management for Aboriginal and Torres Strait Islander people,” Dr Freeman said.

 

“Pharmacists must work collaboratively with Aboriginal Health Organisations to improve the health and wellbeing of Aboriginal and Torres Strait Islander people.”

 

PSA is collaborating with the National Aboriginal Community Controlled Health Organisation (NACCHO) on the Integrating Pharmacists within Aboriginal Community Controlled Health Services to Improve Chronic Disease Management (IPAC) trial.

 

This pioneering project aims to improve chronic disease management by embedding pharmacists within Aboriginal Health Services.

 

PSA’s Aboriginal and Torres Strait Islander Health Services Pharmacist Career Pathway provides training and support to help pharmacists working in these services to optimise health for their patients.

 

PSA will be developing a Reconciliation Action Plan (RAP) in 2019. The RAP will underpin the work PSA does with Aboriginal and Torres Strait Islander people and support members and staff to provide culturally safe workplaces and services.

 

Media contact:  
Jarryd Luke
Senior Communications Officer
0487 922 176

Pharmacists help improve vaccination rates in NSW

January 2, 2019

 

People in NSW can get vaccinated against whooping cough and measles by visiting their local pharmacy, thanks to a move by the NSW Government welcomed by the Pharmaceutical Society of Australia (PSA).

 

As of 1 January 2019, pharmacists are providing diphtheria-tetanus-pertussis (dTpa) and measles-mumps-rubella (MMR) vaccines, in addition to influenza vaccines, to anyone 16 years and over.

 

PSA NSW President Professor Peter Carroll, in welcoming the NSW Government’s announcement, said allowing accredited pharmacists to vaccinate gave people more choice about when and where to get vaccinated.

 

“Allowing accredited pharmacists to vaccinate against whooping cough and measles will further boost NSW’s vaccination rates by making immunisation more accessible.

 

“Particularly in regional and remote NSW, people may have trouble accessing a GP. In addition, some people do not visit a GP regularly, or do not have a GP. Allowing accredited pharmacists to vaccinate will increase vaccination rates and herd immunity within the community.

 

“I congratulate the NSW Government on this initiative which will without doubt increase vaccination rates and help to protect the people of NSW from these preventable diseases.”

 

PSA, the peak national body for pharmacists, has advocated for many years in collaboration with the Pharmacy Guild of Australia to allow pharmacists to deliver more vaccinations.

 

PSA National President Dr Chris Freeman applauded the NSW Government’s initiative to build on the state’s already high vaccination rates.

 

“This brings NSW in line with other states such as the Northern Territory, Queensland, South Australia and Victoria where pharmacists already provide dTpa and MMR vaccinations.”

 

In 2018, the Council of Australian Governments (COAG) Health Council announced their decision to establish a working group to consider a nationally consistent approach to pharmacist administered vaccinations.

 

“A nationally consistent approach to vaccinations will improve access for all Australians,” Dr Freeman said.

 

“PSA is looking forward to working with the Australian Health Protection Principal Committee to make full use of pharmacists’ expertise across the country so they can provide a wider range of vaccinations.”

 

Media contact:

Jarryd Luke

Senior Communications Officer

0487 922 176

Wage stagnation fails to provide fair minimum safety net for pharmacists: PSA

The decision by the Fair Work Commission to stagnate the minimum safety net pay rate for community pharmacists is a completely inadequate reflection of the complex work that pharmacists do, the Pharmaceutical Society of Australia (PSA) says.

 

PSA National President Dr Chris Freeman said, “It is very clear to PSA that the current pharmacy award rate of just over $27 per hour does not reflect the profession’s significant training, expertise and accountability.

 

“While an increase in the award rate is necessary, PSA is cognisant that it should be considered within the context of the broader pharmacy sector and should be met with, at least, a corresponding increase to funding into the pharmacy sector so any base wage increases are affordable.

 

“We urge all pharmacists to discuss fair remuneration with their employers when accepting employment and at regular intervals.”

 

Dr Freeman said the Fair Work Commission ruling was concerned with determining the minimum wage and conditions for pharmacists rather than reflecting the full value of pharmacists as medicines experts.

 

“The issue of fair pay for pharmacists goes far beyond the minimum wage. Pharmacists need to be appropriately remunerated for their significant training as healthcare professionals with the most expertise in the quality use of medicines,” he said.

 

“The recent case PSA put to the Fair Work Commission focused on the change in the scope of practice for the pharmacy profession. While we have seen some increase in the scope of practice of pharmacists, many of the ‘new’ activities are simply a fulfilment of scope of practice.

 

“Our health system has seen a significant change in the complexity of health problems faced by patients and pharmacists are now practising at a deeper and more intense level.

 

“Moving forward there should be some fiscal recognition for pharmacists who are now practising at a deeper level, achieving greater impact than that achieved at initial registration. The current division of base pharmacist wage categories are simply antiquated.

 

“PSA supports the Fair Work Commission’s acknowledgement that there has been an increase in the work value of pharmacists who perform Home Medicines Reviews (HMRs) and Residential Medication Management Reviews (RMMRs) and notes that the Commission has invited further submissions on this issue.”

 

Dr Freeman said, “The role of pharmacists will continue to evolve as pharmacists take more responsibility and accountability for medicines management in the future. Pharmacist remuneration needs to increase to reflect this.

 

“PSA is committed to increasing pharmacist remuneration and a sustainable model for community pharmacy. It is vital that the Government ensures that investment in community pharmacy significantly increases.

 

“PSA will continue to advocate for a substantive increase in remuneration for Australian pharmacists to ensure the role of pharmacists in modern healthcare delivery is fully realised and valued.

 

“Pharmacists should be paid a fair days wage recognising their significant and integral contribution to the health of Australians, without which, our profession will never meet its full potential, promulgating the professional dissatisfaction and disenfranchisement experienced by so many.”

 

Media contact:  
Jarryd Luke
Senior Communications Officer
0487 922 176

Medication safety must be key focus after 2018–19 MYEFO

While healthcare investment in the 2018–19 MYEFO will improve access to medicines for many Australians, the Pharmaceutical Society of Australia (PSA) is concerned that pharmacists, as part of the broader healthcare team, need to be included as an integral component of future investment in the healthcare system.

 

PSA National President Dr Chris Freeman said pharmacists and pharmacies were pillars of the health system and Australia had significant opportunities to make full use of their expertise.

 

“The government’s commitment to making changes to the Medicare Benefits Schedule (MBS) will benefit patients including people with severe eating disorders and those in rural and remote areas,” he said.

 

“We welcome these important changes to the MBS. However, pharmacists continue to be the only AHPRA registered allied health professionals not eligible to provide allied health services through Chronic Disease Management (CDM) items on the MBS.

 

“Medicines play a major role in the care and treatment of patients with chronic disease, so excluding pharmacists from the MBS for these CDM items makes no sense.

 

“PSA calls for pharmacists to be granted MBS access as part of Team Care Arrangements within CDM items to help improve health outcomes for patients.”

 

PSA welcomed the government’s extension of the Health Care Homes Trial for patients with chronic and complex conditions until 30 June 2021.

 

“As an integral element of the Health Care Homes Trial, community pharmacy is enabling people to get the most out of their medicines. However, barriers to pharmacist involvement still need to be addressed within the current model. We look forward to continuing to support pharmacists participating in this important trial,” Dr Freeman said.

 

“We also support the government’s increased investment in aged care to provide better care for our elders.

 

“We know medication management in aged care is a key area for improvement, so it is imperative that pharmacists are embedded within aged care facilities to ensure the safe and effective use of medicines.

 

“These announcements have again ensured that doctors are one of the first cabs off the rank when it comes to additional investment in healthcare. We need to make sure patients are front and centre when healthcare investment is considered.

 

“That is why we have continued to call for investment in medication safety by ensuring pharmacists are embedded within aged care and other settings.

 

“Pharmacists understand how important medicine safety is to residents’ health. By working with doctors, nurses and residents to ensure the right medicines are being taken in the right way at the right time, pharmacists can greatly improve health outcomes.

 

“We call on the government for some of the additional investment in research through the Medical Research Future Fund (MRFF) to focus on medicines safety. Medicines are still a leading cause of harm and hospitalisations and are an under-researched area with substantial gaps existing in the literature.”

 

Media contact:
Jarryd Luke
Senior Communications Officer
0487 922 176

NSW/ACT ATU20 Program and Speakers

Friday 6 March

Dr Claire O’Reilly

9:30am – 11:00am and 2:00pm – 3:30pm (repeat)

 

Synopsis

 

Dr Claire O’Reilly

11:30am – 1:00pm and 4:00pm – 5:30pm (repeat)

 

The session will discuss evidence-based strategies to influence patient health behaviours and referral pathways in the context of depression and mental health more broadly. Additionally, you will be guided on how to use a depression screening tool in the primary care setting.

Prof Glen Maberly

9:30am – 11:00am and 2:00pm – 3:30pm (repeat)

 

Synopsis

 

Prof Glen Maberly

11:30am – 1:00pm and 4:00pm – 5:30pm (repeat)

 

Diabesity describes the link between diabetes and obesity, and is an emerging epidemic in Australia. This session will outline existing and future therapeutic treatments that have the potential to treat this patient group. The importance of early detection and the role of the pharmacist in maximising treatment outcomes will also be outlined. This session will also provide information on the NSW Health Get Healthy Coaching Service.

 

Saturday 7 March

Natalie Raffoul

11:45pm – 12:30pm

 

It’s no secret that heart failure patients have a high rate of re-hospitalisation in the first two weeks post-discharge. Follow heart failure patients through the transition of care journey. Underpinned by Action Item number 5; Improve pharmacist stewardship of medication management to improve outcomes at transitions of care in Pharmacists in 2023, this practical session will look at treatments, management options and integrated care models that maximise patient outcomes.

 

Associate Professor Renee Bittoun

1:30pm – 2:15pm

 

Synopsis

 

Professor Lisa Nissen

2:15pm – 3:30pm

 

This session will feature an original ‘Prophetical’ – a dynamic and entertaining technique for engaging participants deeply. The Prophetical harnesses the power of story to connect, to intrigue, to reveal and to inspire, tapping into the intrinsic problem-solving capacity of the group as a whole. An experience not to be missed!

 

Sunday 8 March

Professor Jennifer Martin

9:00am – 8:45am

 

Join Professor Martin who will outline the pharmacokinetics of Phytocannabinoids and the interaction with the human endocannabinoid system. Professor Martin will discuss evidence-based indications and contra-indications as well as regulatory requirements of pharmaceutically formulated cannabinoid therapy in Australia.

 

Professor Peter Carroll

9:45am – 10:30am

 

Are you a pharmacist vaccinator? Want to know more on the impact of pharmacistled vaccinations? Professor Peter Carroll will provide an update on flu vaccination and outline the enablers for pharmacists as well as opportunities in the future.

 

Professor Lisa Nissen

11:45am – 12:30pm

 

Migraines, are more than just a pain in the head. With the rise of monoclonal antibodies, we have seen the therapeutic application of these agents encompass a number of indications. Professor Nissen will outline how these agents are also progressing the treatment of migraines with CGRP receptor antagonists.

 

Associate Professor David Newby

12:30pm – 1:15pm

 

Synopsis